Deciding on the appropriate pharmacotherapy for the treatment of endometriosis

Carneiro MM, Márcia Mendonça Carneiro
Expert opinion on pharmacotherapy · 2022 · vol. 24(1) , pp. 1–5 · doi:10.1080/14656566.2022.2113383 · PMID:35973977 · W4292170665
letter OA: closed CC0 ⤵ 16 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This review discusses current pharmacotherapy options for endometriosis, examining their efficacy and side effect profiles to guide treatment decisions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (16)

Source provenance

europepmc
last seen: 2026-09-07T06:12:11.729357+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-08-13T06:15:20.060954+00:00
License: CC0 · commercial use OK